Mirum plans FDA submission for hepatitis D treatment after trial success

Mirum Pharmaceuticals says its hepatitis D treatment succeeded in a second pivotal trial.

This was the second of two pivotal trials, which are key studies used to assess a treatment.

The company plans to submit the treatment to the US Food and Drug Administration.

The FDA submission is the next step toward seeking US regulatory review.

Hepatitis D is the condition the treatment is intended to address.

Mirum faces rivals in a growing market for hepatitis D treatments.

That competition could shape the treatment’s prospects if it reaches the market.

The available information does not give a submission date or details about the rival treatments.